Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme : Literature review and future directions
© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology..
Glioblastoma multiforme (GBM) is an aggressive cancer that has been difficult to treat and often requires multimodal therapy consisting of surgery, radiotherapy, and chemotherapy. Chimeric antigen receptor-expressing (CAR-T) cells have been efficacious in treating hematological malignancies, resulting in several FDA-approved therapies. CAR-T cells have been more recently studied for the treatment of GBM, with some promising preclinical and clinical results. The purpose of this literature review is to highlight the commonly targeted antigens, results of clinical trials, novel modifications, and potential solutions for challenges that exist for CAR-T cells to become more widely implemented and effective in eradicating GBM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Neuro-oncology advances - 6(2024), 1 vom: 25. Jan., Seite vdae025 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goutnik, Michael [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigen escape |
|---|
| Anmerkungen: |
Date Revised 16.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/noajnl/vdae025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369765494 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369765494 | ||
| 003 | DE-627 | ||
| 005 | 20240316233112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/noajnl/vdae025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1332.xml |
| 035 | |a (DE-627)NLM369765494 | ||
| 035 | |a (NLM)38486856 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goutnik, Michael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme |b Literature review and future directions |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. | ||
| 520 | |a Glioblastoma multiforme (GBM) is an aggressive cancer that has been difficult to treat and often requires multimodal therapy consisting of surgery, radiotherapy, and chemotherapy. Chimeric antigen receptor-expressing (CAR-T) cells have been efficacious in treating hematological malignancies, resulting in several FDA-approved therapies. CAR-T cells have been more recently studied for the treatment of GBM, with some promising preclinical and clinical results. The purpose of this literature review is to highlight the commonly targeted antigens, results of clinical trials, novel modifications, and potential solutions for challenges that exist for CAR-T cells to become more widely implemented and effective in eradicating GBM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CAR-T cells | |
| 650 | 4 | |a antigen escape | |
| 650 | 4 | |a glioblastoma multiforme | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a tumor microenvironment | |
| 700 | 1 | |a Iakovidis, Alexandria |e verfasserin |4 aut | |
| 700 | 1 | |a Still, Megan E H |e verfasserin |4 aut | |
| 700 | 1 | |a Moor, Rachel S F |e verfasserin |4 aut | |
| 700 | 1 | |a Melnick, Kaitlyn |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Abbas, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jianping |e verfasserin |4 aut | |
| 700 | 1 | |a Ghiaseddin, Ashley P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuro-oncology advances |d 2019 |g 6(2024), 1 vom: 25. Jan., Seite vdae025 |w (DE-627)NLM302151087 |x 2632-2498 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2024 |g number:1 |g day:25 |g month:01 |g pages:vdae025 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/noajnl/vdae025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2024 |e 1 |b 25 |c 01 |h vdae025 | ||